United Therapeutics

United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. The company was founded by Martine A. Rothblatt on June 26, 1996, and is headquartered in Silver Spring, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

United Therapeutics achieves record 2022 performance, eyes revenue doubling

United Therapeutics had a remarkable year in 2022, with strong financial performance and market acceptance of its products. While facing challenges and questions from analysts, UTHR remains focused on growth and innovation.

United Therapeutics reports robust Q1 growth and eyes new opportunities

United Therapeutics (UTHR) showcased strong revenue growth, product performance, and strategic investments in manufacturing facilities and pipeline trials. Challenges include managing factors affecting Tyvaso revenue and patient flow between key products. However, opportunities from new FDA approvals and organ manufacturing advancements position UTHR for continued growth and innovation.

United Therapeutics achieves record revenue, eyes growth beyond hypertension

United Therapeutics delivered exceptional financial performance in Q2 2023, driven by strong revenue growth and strategic product positioning.
The company's focus on combination therapies, expansion into new markets, and commitment to innovation position it well for future success.
Challenges in market saturation and limited drug options in certain therapeutic areas require targeted strategies and continued R&D efforts for sustained growth.
Overall, United Therapeutics' Q2 performance reflects a balance of strengths, challenges, and opportunities that shape its trajectory in the healthcare sector.

United Therapeutics reports record Q3 revenue and growth opportunities

United Therapeutics had a robust Q3 performance with record revenue and growth, driven by strong performance in the Tyvaso franchise. The company is strategically positioned for growth across its commercial business, pipeline programs, and organ technologies. While facing competition and trial challenges, UTHR remains optimistic about its growth potential and opportunities in addressing critical medical needs.

United Therapeutics reports record revenue growth and highlights innovative pipeline

United Therapeutics (UTHR) delivered a strong performance in Q4 2023, showcasing record revenue growth and confidence in its product portfolio. While facing challenges like patient demand fluctuations and potential competition, UTHR remains focused on innovation and growth opportunities in its pipeline.

United Therapeutics reports record revenue and advances in organ manufacturing

United Therapeutics (UTHR) delivered strong financial performance in Q1 2024, driven by revenue growth and strategic capital allocation initiatives.
The company's focus on product innovation, clinical advancements, and organ manufacturing positions UTHR well for future growth and market competitiveness.
While facing challenges in market penetration and product integration, UTHR has opportunities to expand its market presence, enhance treatment options, and pioneer advancements in organ transplantation.

United Therapeutics (UTHR) reports record revenue and strategic growth

United Therapeutics (UTHR) delivered a strong performance in Q2 2024, driven by record revenue and strategic product focus. The company's emphasis on innovation, market competitiveness, and employee satisfaction positions it well for future growth. Challenges in navigating market dynamics and executing key studies require focused attention, while opportunities exist in expanding market share and optimizing capital allocation.

United Therapeutics reports record revenue growth, faces litigation challenges

United Therapeutics delivered a strong performance in Q3 2024, achieving record revenue and significant growth in key product segments.
While facing challenges such as litigation accrual and slower growth in certain product revenues, the company remains well-positioned for future opportunities.
Investors have shown confidence in United Therapeutics, as reflected in the stock appreciation post ASR program, indicating positive market sentiment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

DaVita

Rite Aid

Tempur Sealy International

Twin River Worldwide Holdings Inc

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

5 Stocks in Focus on Remarkable Relative Price Strength

United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why United Therapeutics (UTHR) is Poised to Beat Earnings Estimates Again

United Therapeutics Corporation 
UTHR 2.83%
 may face stiffening competition from generic entrants, which could meaningfully increase pricing pressure and shrink its market share, according to Bank of America Merrill Lynch

Bank Of America Initiates United Therapeutics With Bearing Rating, Cites Unclear Growth Outlook

WESTLAKE VILLAGE, Calif., Nov.  04, 2019  (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that it has achieved the second of four specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil.  Treprostinil Technosphere (“TreT”) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension.  Pursuant to the agreement, MannKind is eligible to earn additional milestone payments up to $25 million upon the achievement of other defined development milestones.  MannKind will also be entitled to receive low double-digit royalties on net sales of TreT.

MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics

United Therapeutics (UTHR) beats estimates on both fronts in the third quarter. Stock rises in response

United Therapeutics (UTHR) Q3 Earnings & Sales Top, Stock Up

United Therapeutics Corporation (UTHR) CEO Dr. Martine Rothblatt on Q3 2019 Results - Earnings Call Transcript

Revenue and earnings fell from the prior-year period, but the drugmaker blew past analysts' estimates thanks to a combination of factors.

How United Therapeutics Trounced Wall Street's Q3 Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 28.63% and 19.94%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Tops Q3 Earnings and Revenue Estimates

Costamare

First American Financial

Intel

Plexus

5 Solid Relative Price Strength Stocks to Make You Rich

Stung by expiring exclusivity agreements for sales of flagship PAH treatment drug Adcirca, United's stock price has been in the doldrums during 2019.

United Therapeutics: In The Doldrums But Plenty Of Reasons To Watch This Stock Closely

United Therapeutics (UTHR) announces acceptance of Trevyent NDA by the FDA for pulmonary arterial hypertension.

United Therapeutics' Trevyent NDA for PAH Accepted by FDA

United Therapeutics (UTHR) beats estimates on both fronts in the second quarter. Loss of exclusivity for Adcirca and lower sales of Remodulin hurts sales.

United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Down Y/Y

United Therapeutics Corporation (UTHR) CEO Dr. Martine Rothblatt on Q2 2019 Results - Earnings Call Transcript

United Therapeutics (UTHR) delivered earnings and revenue surprises of 51.25% and 12.60%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Q2 Earnings and Revenues Beat Estimates

United Therapeutics Corporation (NASDAQ: UTHR)'s shares have shed more than 28% year-to-date, making its valuation attractive, according to Credit Suisse.

Credit Suisse: United Therapeutics Becoming More Fundamentally Driven

The stock has now fallen nearly 30% since the end of March.

Here's Why United Therapeutics Fell 18.1% in May

United Therapeutics (UTHR) delivered earnings and revenue surprises of 35.61% and 9.72%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Beats Q1 Earnings and Revenue Estimates

United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q1 2019 Results - Earnings Call Transcript

United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

United Therapeutics (UTHR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

United Therapeutics discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.

United Therapeutics Discontinues PAH Drug After Study Fails

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

News for United Therapeutics Stock (UTHR)